DRKS00026655
Completed
Not Applicable
Prognostic serum biomarkers by COVID-19
niversity of Debrecen0 sites67 target enrollmentNovember 26, 2021
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- J12.8
- Sponsor
- niversity of Debrecen
- Enrollment
- 67
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Deep frozen serum samples of matched (age, sex, diabetes mellitus, nicotin consume and body weight) patients with SARS\-Cov2 infection and control patients are going to be analised.
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Evaluation of immunity in the evolution of the severe or mild form of COVID-19coronavirusB97.2RBR-62zdkkHospital Universitário de Brasília
Not yet recruiting
Not Applicable
The role of markers(nlr,il-6,d-dimer) in COVID-19 patients and itâ??s co-relationship with oxygenation ,a retrospective observational study in Tertiary care covid ICHealth Condition 1: B972- Coronavirus as the cause of diseases classified elsewhereHealth Condition 2: J09X- Influenza due to identified novelinfluenza A virusHealth Condition 3: J111- Influenza due to unidentified influenza virus with other respiratory manifestationsCTRI/2020/08/027110Vmmc and Safdarjung Hospital
Recruiting
Not Applicable
Biomarkers for prognosis in critically ill COVID-19 patients : a prospective cohort studyower respiratory tract infectionsNL-OMON21322none100
Not yet recruiting
Not Applicable
Study of investigation tools in COVID 19 patients anx how it affects on patients outcomeHealth Condition 1: B972- Coronavirus as the cause of diseases classified elsewhereCTRI/2021/06/034352GCS medical college and hospital centre
Completed
Not Applicable
Evaluation of SARS-CoV-2-specific Serumparameters in Blood Samples of SARS-CoV-2-seronegative Volunteers as well as former Patients with Healed, Asymptomatic, Mild or Severe COVID-19-Courses (HTXCOV-01B)07.1GU09.9GDRKS00025863Heidelberg ImmunoTherapeutics GmbH35